Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Enfusion reported a solid third quarter in 2024, demonstrating a 15% year-over-year revenue growth, reaching $51.2 million.</li><li>This aligns with the company's focus on executing its long-term strategic initiatives, particularly in expanding its footprint into higher-value market segments.</li><li>The adjusted EBITDA also showed a positive trend, totaling $11.1 million, equating to a healthy margin of 21.8%.</li></ul>

Enfusion reported a solid third quarter in 2024, demonstrating a 15% year-over-year revenue growth, reaching $51.2 million.This aligns with the company's focus on executing its long-term strategic initiatives, particularly in expanding its footprint into higher-value market segments.The adjusted EBITDA also showed a positive trend, totaling $11.1 million, equating to a healthy margin of 21.8%.

Enfusion: The 7 Most Significant Forces Steering Its Performance into 2025 & Beyond!

<ul><li>Enfusion, Inc., during its third-quarter 2024 earnings presentation, demonstrated robust progress in executing its strategic initiatives.</li><li>The company achieved a 15% year-over-year increase in revenue, reaching $51.2 million, with notable growth driven by its strategic focus on larger, up-market clients and geographical expansion.</li><li>Despite favorable revenue growth, the minor challenges faced included slower back book expansion, particularly in the Asia-Pacific (APAC) region, due to geopolitical uncertainties and economic conditions, which impacted organic growth.</li></ul>

Enfusion, Inc., during its third-quarter 2024 earnings presentation, demonstrated robust progress in executing its strategic initiatives.The company achieved a 15% year-over-year increase in revenue, reaching $51.2 million, with notable growth driven by its strategic focus on larger, up-market clients and geographical expansion.Despite favorable revenue growth, the minor challenges faced included slower back book expansion, particularly in the Asia-Pacific (APAC) region, due to geopolitical uncertainties and economic conditions, which impacted organic growth.

Enfusion Inc.: Leveraging Managed Services for Faster Monetization To Change The Game! - Major Drivers

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Sailpoint Technologies Holdings / Equity Capital Markets

<ul>
<li>The underwriters amended the terms of this offering with a S-1/A. The price range has been upwardly revised from $19.00-$21.00 to $21.00-$23.00.</li>
<li>Cornerstone investor Dragoneer has a strong track record with IPOs that have participated in. </li>
<li>The upwardly-revised price adjustment is a very bullish sign for the IPO and we have adjusted our early expectations on this deal.</li>
</ul>


The underwriters amended the terms of this offering with a S-1/A. The price range has been upwardly revised from $19.00-$21.00 to $21.00-$23.00.
Cornerstone investor Dragoneer has a strong track record with IPOs that have participated in. 
The upwardly-revised price adjustment is a very bullish sign for the IPO and we have adjusted our early expectations on this deal.


SailPoint, Inc. (SAIL) -- IPO Price Range Increased; Software Order Book Demand Is Fever Pitch

<ul><li>Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance expectations in the medium term.</li><li>The company posted $49.5 million in revenue, marking a 16% year-over-year growth.</li><li>The adjusted EBITDA came in at $10.1 million, translating to a 20.5% margin.</li></ul>

Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance expectations in the medium term.The company posted $49.5 million in revenue, marking a 16% year-over-year growth.The adjusted EBITDA came in at $10.1 million, translating to a 20.5% margin.

Is Enfusion About to Be Snapped Up? Here’s Why Acquirers Could Be Lining Up!

United States

Enfusion, Inc. provides software solutions. The Company offers software-as-a-service platform that allows clients to see and interact with all parts of the investment management lifecycle ranging from portfolio construction, trading, risk management, accounting, and operations. Enfusion serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Enfusion (ENFN US)

Enfusion: The 7 Most Significant Forces Steering Its Performance into 2025 & Beyond!

Enfusion reported a solid third quarter in 2024, demonstrating a 15% year-over-year revenue growth, reaching $51.2 million. This aligns with the...

Baptista Research

Enfusion Inc.: Leveraging Managed Services for Faster Monetization To Change The Game! - Major Drivers

Enfusion, Inc., during its third-quarter 2024 earnings presentation, demonstrated robust progress in executing its strategic initiatives. The...

Baptista Research

SailPoint, Inc. (SAIL) -- IPO Price Range Increased; Software Order Book Demand Is Fever Pitch

Underwriters amend IPO terms, raising price range to $21.00-$23.00; cornerstone investor Dragoneer's track record adds confidence, signaling...

IPO Boutique

Is Enfusion About to Be Snapped Up? Here’s Why Acquirers Could Be Lining Up!

Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Enfusion: The 7 Most Significant Forces Steering Its Performance into 2025 & Beyond!

Enfusion reported a solid third quarter in 2024, demonstrating a 15% year-over-year revenue growth, reaching $51.2 million. This aligns with the...

Baptista Research

Enfusion Inc.: Leveraging Managed Services for Faster Monetization To Change The Game! - Major Drivers

Enfusion, Inc., during its third-quarter 2024 earnings presentation, demonstrated robust progress in executing its strategic initiatives. The...

Baptista Research

SailPoint, Inc. (SAIL) -- IPO Price Range Increased; Software Order Book Demand Is Fever Pitch

​Underwriters amend IPO terms, raising price range to $21.00-$23.00; cornerstone investor Dragoneer's track record adds confidence, signaling...

IPO Boutique

Is Enfusion About to Be Snapped Up? Here’s Why Acquirers Could Be Lining Up!

Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance...

Baptista Research

Underwriters amend IPO terms, raising price range to $21.00-$23.00; cornerstone investor Dragoneer's track record adds confidence, signaling...